Overview

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Idera Pharmaceuticals, Inc.
Collaborator:
Bristol-Myers Squibb
Treatments:
Ipilimumab
Nivolumab